JAZZ - Jazz Pharmaceuticals Non-GAAP EPS of $4.30 beats by $0.11 revenue of $932.88M beats by $30.37M
- Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q2 Non-GAAP EPS of $4.30 beats by $0.11 .
- Revenue of $932.88M (+24.1% Y/Y) beats by $30.37M .
- 2022 total revenue guidance affirmed at $3.5B to $3.7B vs. consensus of $3.6B.
- "We have achieved our net leverage 2 ratio target ahead of our stated timeline and therefore our focus will be to continue to manage the balance sheet through disciplined capital allocation, providing us with further flexibility to pursue corporate development opportunities," said Renée Galá, executive vice president and chief financial officer of Jazz Pharmaceuticals. "Our strong second quarter financial results and top- and bottom-line growth put us well on track to achieve our 2022 financial guidance. Operational excellence will also remain a key area of focus for us as we build the foundation for future growth and progress toward achieving Vision 2025."
For further details see:
Jazz Pharmaceuticals Non-GAAP EPS of $4.30 beats by $0.11, revenue of $932.88M beats by $30.37M